It is my pleasure to invite you to join us in Manchester for The 16th International Congress on Antiphospholipid Antibodies 2019 taking place from 17 – 20 September 2019.
The congress occurs every three years and we have an exciting programme that will review, discuss and debate many exciting and evolving topics that are of great relevance across a range of medical subspecialties including rheumatology, haematology, obstetrics and neurology. The scientific aspects of the congress also span many disciplines including genetics, vascular biology, immunology, diagnostics and thrombosis/heamostasis. Our time together with provide an ideal platform for scientists and clinicians from around the world and multiple disciplines to discuss recent innovative and important research to prioritise research questions, and to set a roadmap for further research in thrombosis and antiphospholipid syndrome (APS).
Manchester is the birthplace of the British National Health Service and in an era of significant political, social and financial challenges for healthcare professionals, is playing a leading role in developing new ways to meet the healthcare needs of the future. We will be discussing recent advances in both the basic and clinical sciences of thrombosis and APS, address findings regarding mechanisms of antibody origin and effect, mechanisms of injury, and clinical trials with new generation oral anticoagulants and immunosuppressive treatments.
A key focus of the congress will be to involve young investigators and the next generation of leaders from clinical and non-clinical disciplines. We believe that capacity building and encouraging new investigators will helps us drive this area forward over the next few years. We also have an exciting patient programme in the congress to help us better understand fully the unmet needs and plan and prioritise future research.
We are looking forward to welcoming investigators, patients and industry partners from around the globe for a vibrant and dynamic discussion over the duration of this congress.